Telperion Partners

Alex has been a principal on every Telperion Partners investment, beginning with Auris Health in 2017 (acquired by Johnson & Johnson in 2019). He shares responsibility for sourcing, structuring relationships with institutional co-investors, and capital formation across the platform's investor base.

He serves as managing member of Telperion Manager LLC and Athelas Manager LLC, the entities through which the platform's investments are organized and, alongside the other principals, holds board observer rights at nearly every portfolio company. He previously served as a director of Uromedica through its 2026 acquisition by Coloplast.

Alex brings a quarter-century of operating and investing experience, including earlier roles at Goldman Sachs (emerging markets research, Brazil) and AT&T Strategic Planning. He is an Adjunct Professor of Real Estate Investments at George Mason University. In parallel, he is a principal of Advantage Properties, Inc., a commercial real estate platform he and Aaron have built into a multi-asset portfolio across the Mid-Atlantic and Southeast.

Aaron has been a principal on every Telperion Partners investment since 2021, including the firm's three Capstan Medical rounds, two Rivermark rounds, and investments in Bright Uro, Mendaera, Verve Medical, HistoSonics, and Spirair, with shared responsibility for sourcing, diligence, investor relationships, and ongoing portfolio oversight.

He serves as managing member of Telperion Manager LLC and Athelas Manager LLC, the entities through which the platform's investments are organized and, alongside the other principals, holds board observer rights at nearly every portfolio company.

Aaron is also a principal of Advantage Properties, Inc., a commercial real estate platform he and Alex have built across the Mid-Atlantic and Southeast. His legal background, approximately a decade at Bingham McCutchen LLP followed by a role as SVP and General Counsel of a New York real estate development firm, informs his approach to deal structuring across the portfolio.

Matt has been a principal on every Telperion Partners investment, beginning with Auris Health in 2017. He brings clinical depth to diligence that capital alone cannot replicate. Most of the platform's investments are in technologies Matt could plausibly use, train others on, or evaluate from direct surgical experience.

He serves as managing member of Telperion Manager LLC and Athelas Manager LLC, and as a board director of Rivermark Medical. Alongside the other principals, Matt holds board observer rights at nearly every portfolio company.

Matt is a board-certified urologist and a Fellow of the American Board of Urology and the American College of Surgeons, with active surgical privileges across eight hospitals in Florida and California. He is the founder of Elite Robotic Surgical Consultants and is an early advisor to several medical device and pathology companies. He serves as a key opinion leader for Intuitive Surgical, Medtronic, Boston Scientific, Teleflex / Neotract, UroMedica, and others. He is the lead U.S. trainer for the ProACT system.

Dean is an academic urologist whose research and clinical interests sit directly inside the platform's most active thesis areas: voiding dysfunction, BPH, sacral neuromodulation, and men's health. He has been a principal on Telperion Partners investments since the first Rivermark round in 2023 and contributes deep clinical evaluation across the urology portfolio.

He serves as managing member of Athelas Manager LLC and, alongside the other principals, holds board observer rights at nearly every portfolio company.

Dean is an Associate Professor of Urology at the University of Toronto, an attending urologist at the University Health Network, Medical Director of the Sexual Health Clinic at Princess Margaret Cancer Centre, and Fellowship Director for functional urology. He has published more than 180 peer-reviewed manuscripts and is the lead author of the Canadian guidelines for Male LUTS/BPH. He is the recipient of the 2022 SIU Innovators Award.